功能成像技术对局部晚期直肠癌新辅助治疗预测与评估价值

doi:10.3760/cma.j.issn.1004-4221.2018.10.016

摘要
图/表
参考文献()
相关文章 (5)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

对于局部晚期直肠癌,新辅助放化疗后行手术切除,再行术后辅助化疗,已发展为标准治疗模式。新辅助治疗可使肿瘤病灶发生不同程度的退缩,部分患者术后病理证实达到完全缓解,有助于增加直肠癌患者根治性手术概率,并降低复发率,改善患者的远期预后。近年来,新辅助治疗疗效的预测和评估,成为临床医生关注的焦点。在影像学方面,常规的形态成像技术,不能够准确反映新辅助放化疗后肿瘤治疗效果,而DWI-MRI、DCE-MRI、PET-CT等功能成像技术不仅能够反映肿瘤退缩程度,还可以反映治疗前后肿瘤功能代谢方面的变化,因而更为准确。现对直肠癌新辅助放化疗影像学疗效评价方法的应用现状进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姜厚军
	朱雅群

关键词 ：直肠肿瘤/新辅助放化疗法, 功能成像, 预测与评估

Abstract：

For locally advanced rectal cancer,neoadjuvant chemoradiotherapy,followed by surgery and postoperative adjuvant chemotherapy has become a standard treatment mode. Neoadjuvant chemoradiotherapy can induce the tumors to shrink to different extent. Partial patients can obtain complete remission validated by postoperative pathological examination,which contributes to increasing the probability of radical surgery for rectal cancer patients,reducing the recurrence rate and improving the long-term clinical prognosis. In recent years,the prediction and evaluation of the clinical efficacy of neoadjuvant therapy has captivated widespread attentions from clinicians. In terms of imaging Methods,conventional morphological imaging techniques cannot accurately assess the clinical efficacy of neoadjuvant chemoradiotherapy,whereas DWI-MRI,DCE-MRI,PET-CT and other functional imaging techniques can not only reflect the degree of tumor shrinkage,but also reveal the changes in the functional metabolism of tumors before and after treatment and yield higher accuracy. In this article,recent application of imaging techniques in the evaluation of clinical efficacy of neoadjuvant chemoradiotherapy for rectal cancer was reviewed.

Key words： Rectal neoplasms/neoadjuvant chemoradiotherapy Functional imaging Prediction and evaluation

收稿日期: 2017-08-17

通讯作者: 朱雅群,Email: szzhuyaqun@sina.com

引用本文:

姜厚军,朱雅群. 功能成像技术对局部晚期直肠癌新辅助治疗预测与评估价值[J]. 中华放射肿瘤学杂志, 2018, 27(10): 945-948.

Jiang Houjun,Zhu Yaqun. Prediction and evaluation value of functional imaging technique in neoadjuvant chemoradiotherapy of locally advanced rectal cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(10): 945-948.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.10.016 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I10/945

[1] Valentini V,Aristei C,Glimelius B,et al. European rectal cancer consensus:multidisciplinary rectal cancer management:2nd European rectal cancer consensus conference (EURECA-CC2)[J].Radiother Oncol,2009,92(2):148-163.DOI:10.1016/j.radonc.2009.06.027.
[2] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J].N Engl J,2004,351(17):1731-1740.DOI:10.1056/NEJMoa040694.
[3] Maas M,Nelemans PJ,Valentini V,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data[J].Lancet Oncol,2010,11(9):835-844.DOI:10.1016/S1470-2045(10)70172-8.
[4] Cazador AC,Coll RF,OlPujol FO,et al. Clinical and cncological results of the pathological complete response in rectal cancer after neoadjuvant treatment[J].Cir Esp,2013,91(7):417-423.DOI:10.1016/j.ciresp.2012.07.014.
[5] Martin ST,Heneghan HM,Winter DC.Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J].Br J Surg,2012,99(7):918-928.DOI:10.1002/bjs.8702.
[6] Tulchinsky H,Rabau M,Shacham-Shemueli E,et al. Can rectal cancers with pathologic T0 after neoadjuvant chemoradiation (ypT0) be treated by transanal excision alone?[J].Ann Surg Oncol,2006,13(3):347-352.DOI:10.1245/ASO.2006.03.029.
[7] Maas M,Beets-Tan RG,Lambregts DM,et al. Wait-and-See policy for clinical complete responders after chemoradiation for rectal cancer[J].J Clin Oncol,2011,29(35):4633-4640.DOI:10.1200/JCO.2011.37.7176.
[8] Renehan AG,Malcomson L,Emsley R,et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project):a propensity-score matched cohort analysis[J].Lancet Oncol,2016,17(2):174-183.DOI:10.1016/S1470-2045(15)00467-2.
[9] O′Neill BD,Brown G,Heald RJ,et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer[J].Lancet Oncol,2007,8(7):625-633.DOI:10.1016/S1470-2045(07)70202-4.
[10] Glynne-Jones R,Hughes R.Complete response after chemoradiotherapy in rectal cancer (Watch-and-Wait):have we cracked the code?[J].Clin Oncol,2016,28(2):152-160.DOI:10.1016/j.clon.2015.10.011.
[11] Denecke T,Rau B,Hoffmann KT,et al. Comparison of CT,MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy:Is there a benefit in using functional imaging?[J].Eur Radiol,2005,15(8):1658-1666.DOI:10.1007/s00330-005-2658-4.
[12] Liu GC,Zhang X,Xie E,et al. The value of restaging with chest and abdominal CT/MRI scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J].Medicine,2015,94(47):e2074.DOI:10.1097/MD.0000000000002074.
[13] Barbaro B,Vitale R,Leccisotti L,et al. Restaging locally advanced rectal cancer with MR Imaging after chemoradiation therapy[J].RadioGraphics,2010,30(3):699-716.DOI:10.1148/rg.303095085.
[14] Arbea L,Díaz-González JA,Subtil JC,et al. Patterns of response after preoperative intensity-modulated radiationtherapy and capecitabine/oxaliplatin in rectal cancer:is there still a place for ecoendoscopic ultrasound?[J].Int J Radiat Oncol Biol Phys,2011,81(2):439-444.DOI:10.1016/j.ijrobp.2010.05.028.
[15] Huh JW,Park YA,Jung EJ,et al. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation[J].J Am Coll Surg,2008,207(1):7-12.DOI:10.1016/j.jamcollsurg.2008.01.002.
[16] Lambregts DM,Maas M,Stokkel MP,et al. Magnetic resonance imaging and other imaging modalities in diagnostic and tumor response evaluation[J].Radiat Oncol,2016,26(3):193-198.DOI:10.1016/j.semradonc.2016.02.001.
[17] Suárez J,Vera R,Balén E,et al. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer[J].Colorect Dis,2007,10(6):563-568.DOI:10.1111/j.1463-1318.2007.01424.x.
[18] Dworak O,Keilholz L,Hoffmann A.Pathological features of rectal cancer after preoperative radiochemotherapy[J].Int J Colorect Dis,1997,12(1):19-23.DOI:10.1007/s003840050072.
[19] García-Figueiras R,Caro-Domínguez P,García-Dorrego R,et al. Prognostic factors and functional imaging in rectal cancer[J].Radiología,2012,54(1):45-58.DOI:10.1016/j.rx.2011.05.017.
[20] Kim SH,Lee JY,Han JK,et al. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer[J].Eur Radiol,2011,21(5):987-995.DOI:10.1007/s00330-010-1989-y.
[21] Curvosemedo L,Lambregts DMJ,Maasi M,et al. Rectal Cancer:Assessment of complete response to preoperative combined radiation therapy with chemotherapy-conventional MR volumetry versus diffusion-weighted MR Imaging[J].Radiology,2011,260(3):734-743.DOI:10.1148/radiol.11102467.
[22] Hong IH,Kim AY,Yu CS,et al. Locally advanced rectal cancer:diffusion-weighted MR tumour volumetry and the apparent diffusion coefficient for evaluating complete remission after preoperative chemoradiation therapy[J].Eur Radiol,2013,23(12):3345-3353.DOI:10.1007/s00330-013-2936-5.
[23] Elmi A,Hedgire SS,Covarrubias D,et al. Apparent diffusion coefficient as a non-invasive predictor of treatment response and recurrence in locally advanced rectal cancer[J].Clin Radiol,2013,68(10):524-531.DOI:10.1016/j.crad.2013.05.094.
[24] Birlik B,Obuz F,Elibol FD,et al. Diffusion-weighted MRI and MR-volumetry-in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer[J].Magn Reson Imag,2015,33(2):201-212.DOI:10.1016/j.mri.2014.08.041.
[25] Genovesi D,Filippone A,Cèfaro G,et al. Diffusion-weighted magnetic resonance for prediction of response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer:Preliminary results of a monoinstitutional prospective study[J].Eur J Surg Oncol,2013,39(10):1071-1078.DOI:10.1016/j.ejso.2013.07.090.
[26] Joye I,Deroose CM,Vandecaveye V,et al. The role of diffusion-weighted MRI and ¹⁸F-FDG PET-CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer:a systematic review[J].Radiother Oncol,2014,113(2):158-165.DOI:10.1016/j.radonc.2014.11.026.
[27] Lim JS,Kim D,Baek SE,et al. Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer[J].Eur Radiol,2012,22(8):1693-1700.DOI:10.1007/s00330-012-2416-3.
[28] Tong T,Sun Y,Gollub MJ,et al. Dynamic contrast-enhanced MRI:use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer[J].J Magn Reson Imag,2015,42(3):673-680.DOI:10.1002/jmri.24835.
[29] Kim SH,Lee JM,Gupta SN,et al. Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer[J].J Magn Reson Imag,2014,40(3):730-737.DOI:10.1002/jmri.24387.
[30] Intven M,Reerink O,Philippens ME,et al. Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation[J].J Magn Reson Imag,2015,41(7):1646-1653.DOI:10.1002/jmri.24718.
[31] Petrillo A,Fusco R,Petrillo M,et al. Standardized Index of Shape (SIS):a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC[J].Eur Radiol,2015,25(7):1935-1945.DOI:10.1007/s00330-014-3581-3.
[32] Martens MH,Subhani S,Heijnen LA,et al. Can perfusion MRI predict response to preoperative treatment in rectal cancer?[J].Radiother Oncol,2015,114(2):218-223.DOI:10.1016/j.radonc.2014.11.044.
[33] Lambrecht M,Deroose C,Roels S,et al. The use of FDG-PET-CT and diffusion-weighted magnetic resonance imaging for response prediction before,during and after preoperative chemoradiotherapy for rectal cancer[J].Acta Oncologica,2010,49(7):956-963.DOI:10.3109/0284186X.2010.498439.
[34] Yoon MS,Ahn SJ,Nah BS,et al. The metabolic response using ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer[J].Radiother Oncol,2011,98(1):134-138.DOI:10.1016/j.radonc.2010.10.012.
[35] Shanmugan S,Arrangoiz R,Nitzkorski JR,et al. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using ¹⁸FDG-PET-CT[J].Ann Surg Oncol,2012,19(7):2178-2185.DOI:10.1245/s10434-012-2248-z.
[36] Kim JY,Kim HC,Park JW,et al. Predictive value of ¹⁸FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy[J].Int J Colorect Dis,2013,28(9):1217-1224.DOI:10.1007/s00384-013-1657-1.
[37] Park J,Chang KJ,Seo YS,et al. Tumor SUVmax normalized to liver uptake on ¹⁸F-FDG PET-CT predicts the pathologic complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J].Nucl Med Mol Imag,2014,48(4):295-302.DOI:10.1007/s13139-014-0289-x.
[38] Bang JI,Ha S,Kang SB,et al. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment[¹⁸F]FDG PET-CT scans in locally advanced rectal cancer[J].Eur J Nucl Med Mol Imag,2016,43(3):422-431.DOI:10.1007/s00259-015-3180-9.
[39] Lee SJ,Kim JG,Lee SW,et al. Clinical implications of initial FDG-PET-CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy[J].Cancer Chemother Pharmacol,2013,71(5):1201-1207.DOI:.DOI:10.1007/s00280-013-2114-0.